ORION CORPORATION STOCK EXCHANGE RELEASE 19 JAN 2011 AT 11.00
EET
In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act,
Orion Corporation publishes an Annual Summary of the stock exchange releases
published by the company in 2010. The releases are available on the internet
website of Orion Corporation, at http://www.orion.fi/sereleases.
Orion points out that part of the information in the releases can have become
out-dated.
Stock Exchange Releases in 2010
Jan 4th 2010 200,000 Orion A-shares converted into B-shares
Jan 19th 2010 ORION CORPORATION: Recommendation by the Nomination Committee
concerning Board of Directors to be elected by the 2010 AGM of
Orion Corporation, 19 Jan 2010
Jan 20th 2010 Annual Summary of Stock Exchange Releases published in 2009
Feb 1st 2010 Orion invites analysts and media to Financial Statement Release
conference on 9 February 2010
Feb 9th 2010 Orion Group Financial Statement Release of 2009
Feb 9th 2010 Notice to the Annual General Meeting of Orion Corporation
Feb 18th 2010 The Board of Directors of Orion Corporation decided on an
incentive plan for key persons
Mar 1st 2010 Orion Corporation: Transfer of 65,606 own B-shares on 1 March 2010
Mar 2nd 2010 Orion Group Annual Report 2009 published
Mar 11th 2010 Orion Corporation: Member of the Board of Directors of Orion
Corporation Leena Palotie passed away
Mar 24th 2010 Orion Corporation: Decisions by the AGM on 24 March 2010
Mar 24th 2010 Orion Corporation: Matti Kavetvuo Vice Chairman of the Board of
Directors. Compositions of Board committees
Apr 1st 2010 Orion comments on FDA release on Stalevo
Apr 8th 2010 Amendment of Section 12 of Articles of Association entered in the
Trade Register
Apr 15th 2010 Orion invites analysts and media to Q1 news conference on Tuesday
27 April 2010
Apr 20th 2010 Dexmedetomidine Phase III program completed with positive results
Apr 27th 2010 Orion Group Interim Report January-March 2010
Apr 30th 2010 1,700,000 Orion A-shares converted into B-shares
May 18th 2010 Change in Orion Group Executive Management Board as of 1 Oct 2010
May 18th 2010 Decision by the Board of Directors to repurchase own shares
Jun 1st 2010 1,100,000 Orion A-shares converted into B-shares
Jun 14th 2010 Orion upgrades full-year outlook for 2010
Jun 15th 2010 Composition of R&D Committee as of 15 June 2010
Jun 17th 2010 20,138 Orion A-shares converted into B-shares
Jun 22nd 2010 Orion and Sun settle patent dispute
Jul 19th 2010 Orion invites analysts and media to Q2 news conference on Tuesday
10 August 2010
Aug 10th 2010 Orion Corporation's publication schedules for financial reporting
in 2011
Aug 10th 2010 Orion Group Interim Report January-June 2010
Aug 13th 2010 435,019 Orion A-shares converted into B-shares
Aug 20th 2010 Orion comments on today's FDA release on safety review of Stalevo®
Sep 1st 2010 Orion: Change in the holding of own shares
Sep 24th 2010 Change in Orion Group Executive Management Board as of 1 Jan 2011
Oct 11th 2010 Orion invites analysts and media to Q3 news conference on Tuesday
26 October 2010
Oct 15th 2010 Disclosure Under Chapter 2 Section 9
Oct 20th 2010 European Medicines Agency has initiated the review of Orion's
dexmedetomidine marketing authorisation application
Oct 26th 2010 Orion Group Interim Report January-September 2010
Nov 1st 2010 Composition of the Nomination Committee of Orion Corporation
Nov 12th 2010 321,946 Orion A-shares converted into B-shares
Dec 15th 2010 Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a
generic version of Orion's proprietary drug Comtan® (entacapone)
in the United States
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler®
pulmonary drugs.
The Group's net sales in 2009 amounted to EUR 772 million. The Company invested
EUR 95 million in research and development. At the end of 2009, the Group had a
total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other
European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
[HUG#1480486]